Latest Pharmaceutical News
Last updated: 08:13:12
The FDA will miss the rare-disease decision deadline for Savara’s candidate after a three-month delay.
Merck and Kelun Biotech’s ADC achieved a survival win in a Phase 3 gastroesophageal cancer trial.
Revolution Medicines’ fast-growing pan-RAS inhibitor Rasonque generated exciting results as a first-line treatment for pancreatic cancer.
Abbott started a trial of its Encantor transcatheter aortic valve, a balloon-expandable system that could complement its existing self-expanding Navitor device.
Johnson & Johnson is set to install the first Ottava robot in a U.S. hospital.
Zimmer Biomet submitted its Monogram robot to the FDA and is targeting clearance next year for the autonomous orthopedic robot.
Capricor Therapeutics received a Complete Response Letter from the FDA for its resubmitted Biologics License Application for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy, stating that the data were insufficient to establish substantial evidence of effectiveness and citing certain other clinical deficiencies.
CEL-SCI’s Multikine received Saudi FDA NADR designation, accelerating its potential commercial launch.
Savara was informed that the FDA will not take action on the Molgramostim Biologics License Application for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) by the PDUFA date.
Late-breaking Johnson & Johnson data in psoriatic arthritis showed that TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness.
Aprea Therapeutics announced interim results from the ongoing first-in-human Phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona.
PMV Pharmaceuticals announced promising updated data from the PYNNACLE Phase 2 pivotal trial of Rezatapopt monotherapy in patients with TP53 Y220C-mutated advanced solid tumors.
Kymera Therapeutics will announce results from the KT-621 BROADEN2 Phase 2b atopic dermatitis trial on November 23, 2026.
Insight Molecular Diagnostics expanded utilization of GraftAssure as the first patient samples arrived for the GALACTIC registry study.
Annovis secured an FDA agreement on its integrated summary of safety plan, combining Alzheimer’s and Parkinson’s data ahead of the Buntanetap New Drug Application.